Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...
An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...
6don MSN
A study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response ...
Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their own electric network, like that seen in the body's nervous system.
News Medical on MSN6d
Study uncovers how MAGE-4 and Pten loss promote aggressive tumor growthA study published in Science Advances reveals a novel strategy that allows tumors to evade the body's immune response critical for their elimination.
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback